• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Janssen Sciencies Ireland UC - Articles and news items

Janssen announces results from its ongoing LATTE-2 study

Industry news / 26 February 2016 / Victoria White

The LATTE-2 study showed that a regimen of two investigational long-acting, intramuscular (IM) formulations of HIV medicines had comparable antiviral activity to 3-drug oral antiretroviral therapy in HIV-1 infected adults…

ViiV and Janssen progress two drug injectable HIV-1 treatment

Industry news / 8 January 2016 / Victoria White

ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine…

J&J announces new global commitments to end HIV infection in girls and women

Industry news / 2 December 2015 / Victoria White

Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls…

Results announced for two drug injectable regimen for HIV maintenance therapy

Industry news / 3 November 2015 / Victoria White

Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen…


EMA validates R/F/TAF MAA for the treatment of HIV-1

Industry news / 21 August 2015 / Victoria White

An MAA for an investigational regimen that combines emtricitabine, tenofovir alafenamide and rilpivirine (R/F/TAF) has been fully validated by the EMA…